1h Free Analyst Time
Heron Therapeutics Inc (HRTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors betterSpeak directly to the analyst to clarify any post sales queries you may have.
The profile contains critical company information including:
- Business description: A detailed description of the company’s operations and business divisions
- Corporate strategy: Analyst’s summarization of the company’s business strategy
- SWOT Analysis: A detailed analysis of the company’s strengths, weakness, opportunities and threats
- Company history: Progression of key events associated with the company
- Major products and services: A list of major products, services and brands of the company
- Key competitors: A list of key competitors to the company
- Key employees: A list of the key executives of the company
- Executive biographies: A brief summary of the executives’ employment history
- Key operational heads: A list of personnel heading key departments/functions
- Important locations and subsidiaries: A list and contact details of key locations and subsidiaries of the company
- Detailed financial ratios for the past five years: The latest financial ratios derived from the annual financial statements published by the company with 5 years history
- Interim ratios for the last five interim periods: The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history
Highlights
Heron Therapeutics Inc (Heron) is a biotechnology company that uses proprietary polymer-based drug delivery platform to develop novel, patient-focused drugs for patients suffering from various types of cancer and pain. Its proprietary Biochronomer technology is a polymer-based drug delivery platform, which improves the therapeutic profile of injectable pharmaceuticals. The company's marketed products include Sustol, an extended-release injection indicated in combination with other antiemetics in adults for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy (MEC); Cinvanti for chemotherapy-induced nausea and vomiting (CINV) prevention and Zynrelef (HTX-011) for the treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults. Heron is headquartered in San Diego, California, the US
Heron Therapeutics Inc Key Recent Developments
Feb 28, 2022: Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Recent Corporate Updates
Nov 03, 2021: Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Recent Corporate Updates
Sep 21, 2021: Heron Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference
Sep 20, 2021: Heron Therapeutics appoints Sharmila Dissanaike, M.D. to the Board
Jun 30, 2021: Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Recent Corporate Updates
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Samples
LOADING...
Companies Mentioned
A selection of companies mentioned in this report includes:
- ProStrakan Group plc
- Fresenius Kabi USA LLC
- Pacira BioSciences Inc
- F. Hoffmann-La Roche Ltd
- Mallinckrodt Pharmaceuticals Ltd
- Eisai Co Ltd
- TerSera Therapeutics LLC
- Merck & Co Inc
- Pfizer Inc
- Helsinn Therapeutics (US) Inc
- Aspen Pharmacare Canada Inc
- GlaxoSmithKline Plc
- Hospira Inc